CC 92252
Alternative Names: CC 92252; DEL 106; IL-2 MuteinLatest Information Update: 28 Sep 2023
Price :
$50 *
At a glance
- Originator Delinia
- Developer Celgene Corporation
- Class Anti-inflammatories; Antipsoriatics; Proteins; Recombinant fusion proteins
- Mechanism of Action Interleukin 2 receptor agonists; Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation; Psoriasis
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for phase-I development in Inflammation in USA (Parenteral)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Psoriasis in Germany (Parenteral)
- 28 Aug 2021 No recent reports of development identified for phase-I development in Psoriasis in Germany (Parenteral)